AMD (age-related macular degeneration) occurs in two forms with distinct mechanisms. The dry form (atrophic, 85–90% of cases) progresses slowly—treatment relies on nutritional supplementation validated by the AREDS2 study and regular ophthalmological follow-up. The wet (neovascular) form, which is less common but more aggressive, involves the proliferation of subretinal neovessels that can lead to rapid vision loss within a few weeks—it is treated exclusively with intravitreal anti-VEGF injections administered by a specialized ophthalmologist. Any change in the central visual field—such as a dark spot or distortion of straight lines on the Amsler grid test—requires an urgent ophthalmological consultation.
The AREDS2 study (NIH, 4,203 patients, 5 years) is the global standard for supplementation in intermediate AMD. The validated formula combines 10 mg of lutein + 2 mg of zeaxanthin + 500 mg of vitamin C + 400 IU of vitamin E + 25 mg of zinc + 2 mg of copper. It reduces the risk of progression to advanced AMD by 25% in patients with intermediate-stage AMD—it does not prevent AMD in healthy individuals. Vitamin E (tocopherols) plays a direct antioxidant role on photoreceptor cells by inhibiting lipid peroxidation in DHA-rich membranes.
Selenium is a cofactor for retinal glutathione peroxidase (GPx)—a first-line enzyme against lipid peroxides generated by chronic photo-oxidation. Epidemiological studies link low serum selenium levels to increased severity of atrophic AMD. Resveratrol activates SIRT1 and Nrf2, inducing the synthesis of glutathione and SOD in retinal pigment epithelium cells, and inhibits pro-inflammatory NF-κB. Animal models show a significant reduction in drusen formation—human clinical trials are underway.
Impaired choroidal microcirculation is a central mechanism in the progression of AMD—the choroid provides 80% of the oxygen supply to the outer retina. Ginkgo biloba (EGb 761, 240 mg/day) improves microcirculation through its flavonoids (quercetin, kaempferol), which inhibit platelet aggregation and improve erythrocyte deformability. Randomized studies show a modest improvement in visual function in early-stage dry AMD—preliminary data, complementary to the AREDS2 formula.
As a dual-solubility antioxidant (both fat-soluble and water-soluble),alpha-lipoic acid penetrates both the membrane and aqueous compartments of retinal cells. Its ability to recycle oxidized vitamins C and E enhances the retinal antioxidant system. At doses of 300–600 mg/day, it is being studied as a supplement to the AREDS2 formula in secondary prevention trials—with promising preliminary results, always in conjunction with structured ophthalmological follow-up.
Modifiable risk factors account for 50% of the attributable risk. Smoking is the most well-documented risk factor: it increases the risk by a factor of 2 to 4 according to meta-analyses, by depleting macular antioxidants and reducing retinal oxygenation. A diet rich in green vegetables (lutein, zeaxanthin) and fatty fish (DHA), and low in saturated fats, is associated with a reduced risk in prospective studies. Sun protection (UV- and blue-light-blocking lenses) and blood pressure control round out preventive measures. Our visual acuity page provides guidance on supplements suitable for each stage.
